Get it on Google Play

MYGN Licenses Cancer Drug Technology to Salmedix

May 24, 2005 7:21 AM EDT Send to a Friend
Myriad Genetics, Inc. (Nasdaq: MYGN) exclusively licensed its technology for using ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login